Key result
Low adiponectin ≤ 1.8 ng/mL links to higher 1-year MACE risk in post-STEMI patients.
Why the study?
Decreased adiponectin predicts adverse left ventricular remodeling and MACEs, prompting evaluation of long-term MACEs following STEMI in relation to adiponectin levels.
Does a low serum adiponectin level predict major adverse cardiac events in non-diabetic STEMI patients?
Cohort (n=73)
Yes
Does a low serum adiponectin level predict major adverse cardiac events in non-diabetic STEMI patients?
Effect estimate: AUC 0.77 (95% CI 0.66-0.89)
p-value: p=0.01
A serum adiponectin level ≤ 1.8 ng/mL during hospitalization is a significant independent predictor of major adverse cardiac events at 1 year in non-diabetic patients surviving a STEMI.
Low adiponectin should not yet guide risk stratification or therapy in non-diabetic STEMI survivors; hypothesis-generating for its independent prognostic value.
Background: A decreased level of adiponectin is known as a predictor of adverse left ventricular remodeling and major adverse cardiac events (MACEs). We evaluated long-term MACEs following ST-segment elevation myocardial infarction (STEMI) in relation to adiponectin levels. Methods: This prospective study included a total of 73 consecutive STEMI patients. Adiponectin, CK, CK-MB, cTnI, CRP, HDL cholesterol, LDL cholesterol, triglycerides, and other routine laboratory parameters were considered, and myocardial revascularization and two-dimensional echocardiography were performed. Subjects were divided into two groups according to their serum adiponectin concentrations. Results: In total, 24 (32.87%) patients suffered from MACEs, 19 (26.02%) with adiponectin value ≤ 1.8 ng/mL (group 1) and 5 (6.84%) with adiponectin value > 1.8 ng/mL (group 2) (p < 0.013). Heart failure (Killip >1) was present in 14 cases (19.17%) in group 1 and in 3 cases (4.1%) in group 2 (p < 0.001). Kaplan–Meier analysis was used to depict the occurrence of MACEs according to the adiponectin threshold identified during hospitalization (1.8 ng/mL). The log-rank test revealed a statistically significant difference in survival between groups (p = 0.013), and the AUC value for adiponectin was 0.77 (95% CI, 0.66–0.89), p = 0.01. Based on univariate logistic regression analysis, adiponectin and BMI were significantly associated with MACEs (p = 0.018, p = 0.034). Multivariate logistic regression analysis shows that serum adiponectin predicts MACEs after STEMI (p = 0.011). Conclusions: We found significant associations between adiponectin levels and MACEs in patients who survived STEMI. The established cut-off value of 1.8 ng/mL for adiponectin during hospitalization identified patients at risk for MACEs.
No takes yet. Share an insight, caveat, or question.
Krasniqi et al. (2025) conducted a cohort in ST-segment elevation myocardial infarction (STEMI) (n=73). Serum adiponectin ≤ 1.8 ng/mL vs. Serum adiponectin > 1.8 ng/mL was evaluated on Major adverse cardiac events (MACEs) (AUC 0.77, 95% CI 0.66-0.89, p=0.01). In non-diabetic patients surviving STEMI, an adiponectin level ≤ 1.8 ng/mL during hospitalization was significantly associated with a higher risk of major adverse cardiac events at 1 year.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: